ACADIA Pharmaceuticals (ACAD) Canaccord Genuity’s 45th Annual Growth Conference summary

Company overview and commercial performance

• Focuses on neurological and rare diseases with two commercial assets: NUPLAZID for Parkinson’s disease psychosis and DAYBUE for Rett syndrome.

• 2023 net sales guidance for both assets combined is over $1 billion.

• Both products are first and only approved drugs in their indications.

• Peak sales potential for commercial assets estimated at $1.5–$2 billion.

• Active in business development to expand the portfolio.

DAYBUE (Rett syndrome) growth and strategy

• Persistency rates remain strong: over 50% at 12 months, above 45% at 18 months, with a plateauing trend.

• 70% of active patients have been on DAYBUE for more than 12 months.

• 987 patients received DAYBUE in Q2; 40% treated at centers of excellence, 60% outside.

• Field force expanded by 30% to target underpenetrated community settings, expecting a more meaningful inflection in patient growth by year-end.

• Ex-U.S. expansion ongoing: approved in U.S. and Canada, EU approval expected Q1 next year, with named patient programs in other regions.

NUPLAZID (Parkinson’s disease psychosis) performance and outlook

• Growth driven by field team execution and direct-to-consumer (DTC) campaigns, including a partnership with Ryan Reynolds.

• 17-fold year-over-year increase in NUPLAZID.com site traffic in Q2.

• DTC is one part of a broader marketing mix; not reliant on terrestrial TV.

• 70–75% of patients are on Medicare, making the product sensitive to the Inflation Reduction Act; price negotiations could begin in 2029.

• Intellectual property protection expected through 2038.